<DOC>
	<DOC>NCT00943072</DOC>
	<brief_summary>This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Subjects at least 18 years of age with centerinvolved macular edema secondary to CRVO with mean central retinal thickness ≥ 250 μm on OCT ETDRS best corrected visual acuity of 20/40 to 20/320 (73 to 24 letters) in the study eye Previous treatment with antiangiogenic drugs in the study eye (Pegaptanib sodium,anecortave acetate, bevacizumab, ranibizumab, etc.) Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye CRVO disease duration &gt; 9 months from date of diagnosis Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1 Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>Retinal vein occlusion</keyword>
	<keyword>CRVO</keyword>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>best-corrected visual acuity</keyword>
	<keyword>Regeneron</keyword>
	<keyword>COPERNICUS</keyword>
</DOC>